Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: Risk factors and impact on outcomes by unknown
RESEARCH ARTICLE Open Access
Inadequate treatment of ventilator-associated
and hospital-acquired pneumonia: Risk factors
and impact on outcomes
Nihal Piskin1*, Hande Aydemir1, Nefise Oztoprak2, Deniz Akduman1, Fusun Comert3, Furuzan Kokturk4
and Guven Celebi1
Abstract
Background: Initial antimicrobial therapy (AB) is an important determinant of clinical outcome in patients with
severe infections as pneumonia, however well-conducted studies regarding prognostic impact of inadequate initial
AB in patients who are not undergoing mechanical ventilation (MV) are lacking. In this study we aimed to identify
the risk factors for inadequate initial AB and to determine its subsequent impact on outcomes in both ventilator
associated pneumonia (VAP) and hospital acquired pneumonia (HAP).
Methods: We retrospectively studied the accuracy of initial AB in patients with pneumonia in a university hospital
in Turkey. A total of 218 patients with HAP and 130 patients with VAP were included. For each patient clinical,
radiological and microbiological data were collected. Stepwise multivariate logistic regression analysis was used
for risk factor analysis. Survival analysis was performed by using Kaplan-Meier method with Log-rank test.
Results: Sixty six percent of patients in VAP group and 41.3% of patients in HAP group received inadequate initial
AB. Multiple logistic regression analysis revealed that the risk factors for inadequate initial AB in HAP patients were;
late-onset HAP (OR = 2.35 (95% CI, 1.05-5.22; p = 0.037) and APACHE II score at onset of HAP (OR = 1.06 (95% CI,
1.01-1.12); p = 0.018). In VAP patients; antibiotic usage in the previous three months (OR = 3.16 (95% CI, 1.27-7.81);
p = 0.013) and admission to a surgical unit (OR = 2.9 (95% CI, 1.17-7.19); p = 0.022) were found to be independent
risk factors for inadequate initial AB. No statistically significant difference in crude hospital mortality and 28-day
mortality was observed between the treatment groups in both VAP and HAP. However we showed a significant
increase in length of hospital stay, duration of mechanical ventilation and a prolonged clinical resolution in the
inadequate AB group in both VAP and HAP.
Conclusion: Our data suggests that the risk factors for inadequate initial AB are indirectly associated with the
acquisition of resistant bacteria for both VAP and HAP. Although we could not find a positive correlation between
adequate initial AB and survival; empirical AB with a broad spectrum should be initiated promptly to improve
secondary outcomes.
Background
Nosocomial pneumonia, which is usually defined as
hospital-acquired pneumonia (HAP), is the second most
frequent nosocomial infection but the first in terms of
morbidity, mortality and cost. It occurs in 8-20% of
intensive care unit (ICU) patients, with an increased fre-
quency and mortality if the patients are mechanically
ventilated [1-4]. Over the past decade, several risk fac-
tors associated with mortality have been detected in
HAP and ventilator-associated pneumonia (VAP). One
of the most consistent and evident prognostic factor
throughout the literature is the accuracy of initial anti-
biotic treatment (AB). By contrast, early aggressive
therapy with adequate broad-spectrum regimens that
optimize therapy against the likely pathogens is asso-
ciated with lower mortality rates and shorter hospital
stay [4-8]. However, despite numerious studies some
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controversies continue to exist about the genuine prog-
nostic impact of initial AB [9-14].
In recent years, international societies and most
recently, the American Thoracic Society jointly with the
Infectious Diseases Society of America, have developed
guidelines for the management of HAP and VAP [2,3].
In spite of the presence of practice guidelines, the per-
centage of inadequate AB varies in the literature from
10% to 73% [8-11,13-18]. The presence of multidrug-
resistant bacteria is the primary reason that patients with
VAP and HAP receive inadequate AB [5], however other
factors that contribute to inadequate AB are not well
defined. Therefore, we aimed to identify the possible risk
factors for inadequate initial AB in both HAP and VAP
and to determine its subsequent impact on outcomes.
Methods
Patients and setting
This retrospective cohort study was conducted at
Zonguldak Bulent Ecevit University Hospital, a 524
bed referral and tertiary hospital, from January 2005 to
January 2008. Patients were enrolled in the study if they
were >16 years of age and diagnosed with VAP or HAP
irrespective of the diagnosis at admission. Only the first
episode of pneumonia was taken into account and no
community acquired pneumonia cases were included.
The study was approved by the Zonguldak Bulent Ecevit
University Hospital Ethics Committee. The need for
informed consent was waived due to the retrospective
observational nature of the study.
For each patient clinical, radiological and microbio-
logical data were collected. The following characteristics
were retrieved from patient records: age, sex, underlying
diseases, antibiotic usage in the previous three months,
Acute Physiological Score Chronic Health Evaluation
(APACHE) II at onset of pneumonia, length of hospital
and ICU stays, presence of invasive procedures, duration
of mechanical ventilation, presence of an other site
infection, microbiological culture results, fever and/or
other clinical symptoms resolution dates and mortality.
Definitions
Hospital-acquired pneumonia was diagnosed on the
basis of Centers for Disease Control and Prevention
clinical criteria [19]. Pneumonia was considered ventila-
tor associated when it occurred 48 hours after starting
mechanical ventilation and it was known to have not
been incubating before the initiation of MV. Pneumonia
was defined as early-onset if it started within 4 days of
admission, in accordance with the American Thoracic
Society/Infectious Disease Society of America guidelines
[2,3]. Quantitative cultures of respiratory samples
obtained at the time of diagnosis were used to diagnose
pneumonia. Inadequate AB was defined as, at least one
bacterial isolate not covered by any initial antibiotic, or
when the pathogen was resistant to all initial empiric
antimicrobial agents. In culture negative cases, patients’
records were evaluated and appropriateness of AB was
decided according to resolution of clinical and labora-
tory signs of pneumonia with the initial regimen that
had been pursued or changed. AB was modified as soon
as susceptibility testing results were available or if the
clinical and radiological signs of pneumonia did not
improve, mainly within 48–72 hours. The total number
of deaths within 28 days after the onset of pneumonia
and during hospitalization were defined as 28-day
mortality and in-hospital mortality respectively.
Microbiological data
Microbiological data for the patients was obtained from
cultures of sputum, transendotracheal aspirates (TA),
blood, pleural fluids and bronchoalveolar lavage (BAL)
fluids. The bacteriological diagnosis required the follow-
ing criteria: Sputum and TA cultures growing ≥ 105
colony-forming units (cfu)/ml of bacteria, BAL cultures
growing 104 cfu/ml of bacteria, blood or pleural fluid
cultures revealing the same pathogen with the respira-
tory samples. Appropriate specimens of sputum and TA
to be taken into consideration for diagnostic testing
required a white blood cell count of >25 and <10 epithe-
lial cells per low-power examination field. Bacterial iden-
tification and susceptibility testing were performed by
standard methods. The identification of “mouth flora”
was considered as culture negative.
Statistical analysis
Statistical analysis was performed with SPSS 18.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). Continuous vari-
ables were expressed as mean ± standard deviation and
categorical variables as numbers and percentages. Con-
tinuous variables were compared with the Independent
Sample T test or Mann–Whitney U test and categorical
variables were compared using Pearson's Chi-square test
or Fisher’s Exact Chi-square test. A P value of less than
0.05 was considered statistically significant for all tests.
Forward stepwise logistic regression model was per-
formed to assess the independent risk factors for inad-
equate initial antibiotic treatment in both HAP and VAP
patients. Survival analysis was performed using Kaplan-
Meier method with Log-rank test.
Results
During the study period 348 patients met the inclusion
criteria in whom 218 patients developed HAP and 130
patients developed VAP. The mean age of the patients
was 63.56 ± 15.17 and 62.9% were male. The most fre-
quent admission diagnoses included respiratory diseases
(namely COPD, ARDS or acute respiratory failure)
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(32.3%), neurological diseases (17.7%), malignancy (13.1%)
in VAP patients and respiratory diseases (34.9%), malig-
nancy (20.2%) and metabolic diseases (27.1%) in HAP
patients. Eighty six (66%) patients in VAP group and 90
(41.3%) patients in HAP group received inadequate initial
AB. Characteristics of patients with HAP and VAP with
regard to the adequacy of empirical AB are summarized
in Tables 1 and 2 respectively. Age, sex, comorbidities
and admission diagnosis were not statistically different
between treatment groups in either HAP or VAP patients.
In all VAP cases TA and/or BAL cultures were per-
formed. While for the HAP group, TA cultures were per-
formed in 45 patients and BAL cultures were performed
in 7 patients, the remaining samples were all sputum
cultures. Of the 130 patients with VAP, 13 (10%) were
culture negative, eight patients (6.1%) had polymicrobial
infection and 92 (78.6%) patients were infected by a
multi-drug resistant pathogen. The number of cultures
which grew non-fermenting gram-negative bacilli was
higher in the inadequate AB group but the difference
was not statistically significant (Table 3). Of the 218
patients with HAP, 124 (56.9%) were culture negative,
nine patients (4.1%) had polymicrobial infection and 67
(30.7%) patients were infected by a multi-drug resistant
pathogen. Totally 103 pathogens were isolated from 94
patients. The isolated pathogens are presented in Table 3.
The regimens of empiric antibiotics are summarized in
Table 4. Thirty three (25.4%) patients in VAP group and
13 (5.9%) patients in HAP group received an anti-
biotic combination with a glycopeptide antibiotic. Among
the patients who received inadequate initial AB, anti-
biotic therapy was modified 4.84 ± 2.49 and 3.80 ±
2.49 days after the onset of pneumonia in VAP and HAP
patients respectively.
As the number of culture negative pneumonias were
high especially in the HAP group, we also performed the
analysis in “culture positive patients only” in both HAP
and VAP to determine whether the risk factors differed
based on culture positivity. The results are presented
in Table 5.
To define the independent risk factors for inadequate
initial AB in both HAP and VAP; multiple logistic
regression analysis was performed and age, gender, type
of ICU and/or general ward, presence of underlying dis-
eases, presence of central venous catheterization and
mechanical ventilation, duration of intubation (for VAP
patients only), duration of hospitalization before onset of
pneumonia, previous antibiotic usage in the previous
three months, APACHE II score at onset of pneumonia,
diagnosis of pneumonia (late-onset) and presence of
multi-drug resistant bacteria were included to the model.
There were no multicolinearity in the variables included
Table 1 Characteristics of 218 patients with HAP with regard to the adequacy of empirical antibiotic treatment
Characteristics Adequate treatment n = 128 Inadequate treatment n = 90 p
Age (years) 61.84 ± 14.66 64.44 ± 13.49 0.189
Sex (male) 84 (65.6) 58 (64.4) 0.857
Surgical unit 24 (68.6) 11 (31.4) 0.269
Underlying diseases
Diabetes mellitus 26 (20.3) 14 (15.6) 0.474
COPD 32 (25.0) 19 (21.1) 0.613
Chronic renal failure 14 (10.9) 10 (11.1) 1.000
Congestive heart failure 15 (11.7) 16 (17.8) 0.287
Cerebrovascular disease 7 (5.5) 10 (11.1) 0.203
Malignancy 24 (18.8) 22 (24.4) 0.398
Central venous catheterization 37 (28.9) 35 (38.9) 0.123
Urinary catheterization 88 (68.8) 66 (73.3) 0.464
Late-onset pneumonia 78 (60.9) 72 (80.0) 0.003
Acquisition of other site infection 21 (16.4) 20 (22.2) 0.365
Previous antibiotic usage 42 (32.8) 34 (37.8) 0.449
Culture proven pneumonia 43 (33.6) 51 (56.7) 0.001
MDR bacteria 29 (22.7) 38 (42.2) 0.002
Polymicrobial etiology 1 (0.8) 8 (8.9) 0.004
Length of stay before HAP 7.09 ± 5.07 8.52 ± 5.26 0.003
APACHE II score 12.68 ± 5.79 14.63 ± 6.59 0.024
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in the regression model. Multiple logistic regression
revealed that the risk of inadequate initial AB in HAP
patients was more than twice as large among patients
with late-onset HAP (OR = 2.35 (95% CI, 1.05-5.22; p =
0.037) and the risk was also found to be significantly
associated with the higher APACHE II score at the onset
of HAP (OR = 1.06 (95% CI, 1.01-1.12); p = 0.018). In
VAP patients; antibiotic usage in the previous three
months (OR = 3.16 (95% CI, 1.27-7.81); p = 0.013) and
admission to a surgical unit (OR = 2.9 (95% CI, 1.17-
7.19); p = 0.022) were found to be independent risk
factors for inadequate initial AB.
Sixty eight (31.2%) patients out of 218 died in the
HAP group and 88 (67.7%) patients died in the VAP
group. In the HAP group 95 (43.6%) patients were ad-
mitted to an ICU during their hospital stay and 54
(56.8%) of these died. The remaining 123 patients were
followed in other wards and 14 (11.4%) of these died.
The difference was statistically significant (p < 0.001).
The outcome measures of patients who did and did not
receive adequate initial AB are summarized in Table 6.
No statistically significant difference in crude hospital
mortality was observed between the groups in both
VAP and HAP (Table 6). The pneumonia related mortal-
ity also did not reach statistical significance by day 28
after the diagnosis of pneumonia in either HAP or
VAP [25.2% (30/119) with adequate initial AB versus
39.5% (32/81) with inadequate initial AB in HAP
Table 2 Characteristics of 130 patients with VAP with regard to the adequacy of empirical antibiotic treatment
Characteristics Adequate treatment n = 44 Inadequate treatment n = 86 p
Age (years) 65.64 ± 16.42 64.15 ± 16.83 0.628
Sex (male) 29 (65.9) 48 (55.8) 0.358
Surgical unit 22 (45.8) 26 (54.2) 0.044
Underlying diseases
Diabetes mellitus 6 (13.6) 13 (15.1) 1.000
COPD 15(34.1) 18 (20.9) 0.156
Chronic renal failure 1 (2.3) 4 (4.7) 0.672
Congestive heart failure 7 (15.9) 15 (17.4) 1.000
Cerebrovascular disease 5 (11.4) 16 (18.6) 0.418
Malignancy 6 (13.6) 13 (15.1) 1.000
Central venous catheterization 34 (77.3) 62 (72.1) 0.671
Urinary catheterization 43 (97.7) 84 (97.7) 1.000
Late-onset VAP 36 ( 81.8) 75 (87.2) 0.575
Presence of other site infection 12 (27.3) 42 (48.8) 0.030
Previous antibiotic usage 12 (27.3) 39 (45.3) 0.071
Culture proven pneumonia 37 (84.1) 80 (93.0) 0.128
Polymicrobial etiology 2 (4.5) 6 (7.0) 0.186
MDR bacteria 32 (72.7) 60 (69.8) 0.883
Length of stay before VAP 12.61 ± 11.20 14.31 ± 10.348 0.138
APACHE II score 16.39 ± 6.71 16.81 ± 6.63 0.730
Table 3 Microorganisms recovered from patients with HAP and VAP
Bacteria HAP (n = 103)* VAP (n = 125)*
Adequate n = 49 Inadequate n = 54 p Adequate n = 41 Inadequate n = 84 p
Acinetobacter spp 8 (7.8) 13 (12.6) 0.499 13 (10.4) 37 (29.6) 0.383
Pseudomonas spp 10 (9.7) 14 (13.6) 9 (7.2) 21 (16.8)
S. aureus 12 (11.6) 7 (6.8) 10 (8) 13 (10.4)
S.pneumoniae 6 (5.8) 5 (4.8) 1 (0.8) 5 (4)
K. pneumonia 3 (2.9) 3 (2.9) 3 (2.4) 2 (1.6)
E.coli 6 (5.8) 5 (4.8) 2 (1.6) 4 (3.2)
Others 4 (3.9) 7 (6.8) 3 (2.4) 2 (1.6)
n = Number of microorganisms in patient groups.
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patients (p = 0.519) (Figure 1) and 75.0% (30/40) with
adequate initial AB versus 71.2% (42/59) with inadequate
initial AB in VAP patients (p = 0.847) (Figure 2)]. In VAP
patients median survival time after VAP onset was 13 days
with adequate initial AB and 14 days with inadequate
initial AB (Figure 1). In HAP patients median survival
time after HAP onset was 26 days with adequate initial
AB and 22 days with inadequate initial AB (Figure 2).
Discussion
Despite numerious studies in the literature, most of
our knowledge about the risk factors and prognostic
impact of inadequate initial AB was based on studies
of VAP because well-conducted studies involving
patients who are not undergoing mechanical ventilation
are lacking. Similarly the American Thoracic Society/
Infectious Diseases Society of America evidence-based
guidelines for nosocomial pneumonia are mainly based
on studies of VAP but it is recommended to treat
patients who were not intubated or undergoing mechan-
ical ventilation, in the same manner as those with
VAP [3]. Although treatment alternatives are similar,
in our study we planned to evaluate the risk factors
for inadequate initial AB and the impact of adequacy
Table 4 Antimicrobial agents used in patients with HAP and VAP










Carbapenems 31 (24.2) 16 (17.8) 0.004 20 (45.5) 18 (20.9) <0.001
Third generation cefalosporine 31 (24.2) 27 (30.0) 4 (9.1) 20 (23.3)
β-lactam + β- lactamase inhibitor 35 (27.3) 21 (23.3) 14 (31.8) 26 (30.2)
Quinolone 21 (16.4) 16 (17.8) 0 10 (11.6)
β-lactam in combination with quinolone 1 (0.8) 9 (10.0) 0 9 (10.5)
Aminoglycoside in combination with carbapenem or β-lactam 9 (7.0) 1 (1.1) 6 (13.6) 3 (3.5)
Table 5 Characteristics of culture positive patients with HAP and VAP with regard to the adequacy of empirical
antibiotic treatment
Characteristics HAP (n = 94) VAP (n = 117)
Adequate treatment
n = 43 (%)
Inadequate treatment
n = 51 (%)
p Adequate treatment
n = 37 (%)
Inadequate treatment
n = 80 (%)
p
Age (years) 60.67 ± 16.04 65.14 ± 13.75 0.167 63.59 ± 16.65 63.85 ± 17.07 0.907
Sex (male) 32(74.4) 37 (72.5) 1.000 24 (64.9) 45 (56.3) 0.497
Surgical unit 9 (20.9) 8 (15.7) 0.697 21 (56.8) 25 (31.3) 0.015
Underlying diseases
Diabetes mellitus 5 (11.6) 8 (15.7) 0.789 5 (13.5) 11 (13.8) 1.000
COPD 13 ( 30.2) 10 (19.6) 0.341 11 (29.7) 17 (21.3) 0.443
Chronic renal failure 5 (11.6) 4 (7.8) 0.727 0 (0) 3 (3.8) 0.551
Congestive heart failure 4 (9.3) 9 (17.6) 0.386 6 (16.2) 13 (16.3) 1.000
Cerebrovascular disease 1 (2.3) 9 (17.6) 0.019 3 (8.1) 15 (18.8) 0.227
Malignancy 6 (14.0) 9 (17.6) 0.838 6 (16.2) 11 (13.8) 0.944
Central venous catheterization 16 (37.2) 22 (43.1) 0.710 30 (81.1) 58 (72.5) 0.442
Urinary catheterization 33 (76.7) 37 (72.5) 0.820 37 (100) 78 (97.5) 1.000
Late-onset pneumonia 34 (79.1) 46 (90.2) 0.223 34 (91.9) 72 (90) 1.000
Acquisition of other site infection 12 (27.9) 11 (21.6) 0.637 11 (29.7) 42 (52.5) 0.036
Previous antibiotic usage 20 (46.5) 23 (45.1) 1.000 11 (29.7) 36 (45.0) 0.173
MDR bacteria 29 (67.4) 38 (74.5) 0.599 32 (86.5) 60 (75) 0.243
Polymicrobial etiology 1 (2.3) 8 (15.7) 0.036 2 (5.4) 6 (7.5) 1.000
Length of stay before HAP 7.6 ± 4.3 9.18 ± 5.8 0.194 13.89 ± 11.56 14.88 ± 10.34 0.313
APACHE II score 12.7 ± 5.83 14.92 ± 5.83 0.031 16.08 ± 6.94 16.69 ± 6.72 0.654
Exitus 16 (37.2) 24 (47.1) 0.452 27 (73) 53 (66.3) 0.608
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of initial AB on the prognosis of patients with HAP and
VAP separately.
In this study 66.6% of patients in VAP and 41.3% of
patients in HAP received inadequate initial AB. The
percentage of patients who received inadequate initial
AB is quite variable in the previously published studies
and changes from 10% to 73% [8-11,13-18]. The know-
ledge regarding the colonization of patients, the need
to limit selection pressure and the sensitivity profile of
the suspected pathogens may influence the frequency of
inappropriateness of initial AB.
We identified higher APACHE II score and late-onset
pneumonia as independent risk factors for inadequate
initial AB for patients with HAP. Although severity indi-
ces are not always mentioned in studies regarding the
adequacy of AB of pneumonia, patients with higher se-
verity are considered to be at high risk of poor outcome
and they are also likely to be infected by more resistant
bacteria [10,11]. Similarly late-onset nosocomial pneu-
monia is caused most frequently by hospital-acquired and
often MDR pathogens [20-22]. The potential involvement
of more resistant bacteria in the late-onset pneumonia is
more likely to lead to inadequate treatment with trad-
itional antibiotic regimens [4,6,8,22]. However, we did
not find such association in late onset pneumonia
regarding the adequacy of initial AB and susceptibility
patterns of the isolated pathogens when we performed
the analysis in culture positive patients only. This con-
flicting result may be explained by the distribution of
MDR bacteria within the groups. In our study cohort
the presence of MDR bacteria was higher in the inad-
equate treatment arm in HAP patients and this was
statistically significant. But this significance could not
be shown when only culture positive HAP patients
were analyzed. So we may conclude that the causative
pathogens in late-onset pneumonia in culture negative
HAP patients were resistant to the initial empiric AB.
Although the presence of polymicrobial etiology were
found to be associated with inadequate initial AB in
HAP patients both in general and in the subgroup
analysis of the culture positive patients, it was not deter-
mined as an independent risk factor. We believe that
this may be due to the small number of patients with
polimicrobial etiology.
Table 6 Outcome of patients who did and did not receive adequate antimicrobial therapy










In hospital mortality (n,%) 32 (25.8) 35 (38.9) 0.056 32 (72.7) 56 (65.1) 0.497
Length of total hospital stay 19.61 ± 14.40 24.22 ± 13.70 0.001 28.57 ± 23.66 45.00 ± 49.30 0.0091
Length of stay after the diagnosis of pneumonia 12.52 ± 11.14 15.70 ± 11.21 0.010 16.45 ± 18.23 30.71 ± 46.21 0.034
Duration of intubation 19.11 ± 19.74 32.14 ± 49.51 0.050
Resolution of fever and other symptoms 2.40 ± 2.91 4.96 ± 7.79 <0.001 5.70 ± 5.50 9.09 ± 10.33 0.044
                                Time after HAP onset (days) 
Figure 1 Kaplan-Meier analysis of empirical antimicrobial
treatment of HAP according to 28-day mortality (p = 0.519)
log rank test.
Figure 2 Kaplan-Meier analysis of empirical antimicrobial
treatment of VAP according to 28-day mortality (p = 0.847)
log rank test.
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For patients with VAP previous antibiotic usage and
admission to a surgical unit were found to be independ-
ent risk factors for inadequate AB. Previous antibiotic
exposure is one of the most evident risk factors for
nosocomial infections due to antibiotic-resistant bac-
teria, and it was reported as an independent risk factor
for inadequate AB in most of the previously published
studies [6,10,22-24]. “Admission to a surgical ICU” as
being a risk factor for inadequate AB is more difficult to
explain. The separation of patients into medical and sur-
gical units without identifying the performed surgical
procedure may have affected the analysis of risk factors.
In our study cohort, all of the identified risk factors
were shown to be indirectly associated with the acquisi-
tion of resistant bacteria for both VAP and HAP. How-
ever, in contrast to the results of other previously
published studies, multivariate analysis showed that,
presence of MDR bacteria was not an independent risk
factor for both of the groups, [5,8]. This contradictory
finding may be due to the MDR Acinetobacter spp. out-
break which had just begun early in the study period in
our ICUs. This could also be a possible explanation of
high rates of inadequate therapy in our study population
in general. We reevaluated the empiric treatment
choices after the antibiotic susceptibility profile of the
epidemic clone had been identified. For some of the iso-
lates colistin was the only drug of choice but since colis-
tin was unavailable in the market, in Turkey at the time
of the study, we were not able to use it as an empirical
treatment option. As a result the presence of MDR bac-
teria was high in both of the treatment groups and
the difference regarding the frequency of MDR bacteria
between groups did not reach statistical significance.
In patients with HAP, presence of MDR bacteria was
associated with inadequate AB but in the final multi-
variate model this was not significant. Although we have
included both culture positive and culture negative
patients in the risk factor analysis, the impact of pres-
ence of MDR bacteria did not change when the analysis
was performed in culture proven patients only.
In this study, we were not able to find any statistically
significant difference in mortality rates between patients
who received inadequate initial AB and patients who
received adequate initial AB for both HAP and VAP.
Available studies evaluating the impact of empirical AB
have produced conflicting results; some found positive
correlation between adequate empirical AB and survival,
whereas others did not [8-15]. These contradictory
results are probably ascribable to differences in patients
and pathogens responsible for pneumonia; since in the
studies those found higher mortality rates when AB was
inadequate, the patients who received inadequate AB
were the ones with pneumonia caused by the most diffi-
cult to treat microorganisms [5,11]. In a prospective
study of patients with late-onset VAP; it was reported
that infection due to non-fermenting gram-negative
bacilli was the most important predictor of in-hospital
mortality [22]. These pathogens were also the most com-
mon isolates in our study. However, the frequency of
non-fermenting gram-negative bacilli in the inadequate
and adequate AB groups was not significantly different
and this may have affected the survival results. Ano-
ther reason may be the difference in the definition of
adequate AB as in some studies adequate AB was
defined as AB with a favorable clinical response and in
others it is described as microbiological recovery of sus-
ceptible organisms to the empirical antibiotic regimen.
In the present study we used both of these definitions;
in culture positive patients the adequacy of antibiotics
were defined according to the results of the antimicro-
bial susceptibility testing whereas in culture negative
patients clinical response to the empiric antibiotic regi-
men was taken into consideration. However the assos-
ciation between the adequacy of the initial AB and
survival did not change when the analysis was performed
in culture positive patients only for both VAP and HAP.
In our study cohort although we could not find a posi-
tive correlation between adequate initial antimicrobial
therapy and survival, we showed a significant increase in
ICU length of stay, duration of mechanical ventilation
and a prolonged clinical resolution in the inadequate AB
group for both VAP and HAP. Other researchers also
reported an increased length of stay and increased dur-
ation of mechanical ventilation when initial AB was
inadequate in comparison with adequate AB [6,10]. Only
in one study evaluating the outcome of patients with
VAP, length of ICU and hospital stays were found to
be similar in patients who did and did not receive ad-
equate initial AB [11]. For patients receiving adequate
AB, it was reported that clinical resolution of pneumonia
usually begins during the first several days of treat-
ment [6,25]. Our results were correlated with the litera-
ture, besides we showed a significant prolongation of
the clinical resolution when the initial antibiotic therapy
was inadequate.
The present study has several limitations. Its retro-
spective design is a limitation, since it was not possible
to conduct an accurate analysis of any changes in the
empirical AB regimens. On the other hand, the retro-
spective feature could have been an advantage as the
prescription of initial AB was not influenced by a pro-
spective evaluation during which a large spectrum initial
AB could have been chosen. Another limitation is the
impact of specific pathogens on the adequacy of initial
AB and survival could not be performed because stratifi-
cation into smaller groups would complicate entry in the
logistic regression model, as each group would have a
very small number of cases.
Piskin et al. BMC Infectious Diseases 2012, 12:268 Page 7 of 9
http://www.biomedcentral.com/1471-2334/12/268
Conclusions
In the present study, late-onset pneumonia and APA-
CHE II score at the onset of HAP were found to be
independent risk factors for inadequate initial AB in
patients with HAP whereas previous antibiotic usage
and admission to a surgical unit were found to be asso-
ciated with inadequate initial AB in VAP. Our data sug-
gests that the risk factors for inadequate initial AB were
indirectly associated with the acquisition of resistant
bacteria for both VAP and HAP. Moreover, patients who
received inadequate initial AB with VAP or HAP, had a
longer duration of hospital stay and an increased clinical
resolution time. Our findings support the importance
of investigating the local ecology by active surveillance
cultures and follow-up of susceptibility patterns to estab-
lish adequate empirical AB. Therefore, consideration
should be given to the empirical use of a broader-
spectrum antibiotic that has not previously been admi-
nistered, especially for the coverage of resistant gram-
negative bacteria in order to minimize the occurrence of
inadequate AB.
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